NASDAQ$BMRN
BioMarin Pharmaceutical Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported total revenues of $477 million, driven by growth in Palynziq and Aldurazyme, while Vimizim and Naglazyme revenues decreased due to order timing and COVID-19 impacts.
BioMarin announced financial results for Q3 2020, with total revenues of $477 million. GAAP Net Income was $784.8 million, and Non-GAAP Income was $98.7 million. The company is working with health authorities regarding valoctocogene roxaparvovec and anticipates sharing Phase 3 study results in Q1 2021.
- Total revenues reached $477 million.
- GAAP Net Income was $784.8 million due to tax benefits.
- Non-GAAP Income increased to $98.7 million.
- Valoctocogene roxaparvovec's Phase 3 study results are expected in early 2021.
Headline financials
Revenue & EPS history
BioMarin · Revenue · Quarterly
$477M
Revenue by segment
BioMarin · $461M total across 6 segments · Q3 2020
- VIMIZIM$148M-9.5%32.1%
- KUVAN$124M+2.9%26.9%
- NAGLAZYME$76.3M-19.2%16.6%
- PALYNZIQ$46.1M+91.3%10.0%
- ALDURAZYME$40.9M+79.4%8.9%
- BRINEURA$25.4M+28.3%5.5%
Forward guidance
BioMarin revised its full-year 2020 financial guidance due to the impact of COVID-19 and the absence of valoctocogene roxaparvovec revenue contributions. Total revenue is now expected to be between $1.81 billion and $1.87 billion.
Tailwinds
- GAAP Net Income guidance increased to $760 million - $820 million.
- Non-GAAP Income guidance increased to $280 million - $330 million.
Headwinds
- Total Revenues revised to $1.81 billion - $1.87 billion from $1.85 billion - $1.95 billion.
- Vimizim Net Product Revenues revised to $515 million - $545 million from $530 million - $570 million.
- Cost of Sales (% of Total Revenues) revised to 26% - 28% from 20% - 21%.
- Research and Development Expense revised to $630 million - $670 million from $675 million - $725 million.
- Selling, General and Administrative Expense revised to $725 million - $765 million from $780 million - $830 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.6%
Avg return
30 days after
44%
30 / 68 earnings
Positive
+9.0%
Q3 2014
Best reaction
-10.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | +0.0% | +1.2% | |
| Q4 2025 | -2.7% | -1.9% | -11.7% | |
| Q3 2025 | +1.4% | +1.7% | +5.4% | |
| Q1 2025 | -1.3% | -5.4% | -7.4% | |
| Q4 2024 | +4.8% | +8.5% | +8.6% | |
| Q3 2024 | -4.9% | -5.0% | -6.7% | |
| Q2 2024 | +3.2% | +5.3% | +6.7% | |
| Q1 2024 | -10.7% | -10.8% | -18.0% | |
| Q4 2023 | +3.0% | +2.4% | -3.9% | |
| Q3 2023 | -2.2% | -6.4% | +13.5% | |
| Q2 2023 | +1.6% | +1.1% | +7.1% | |
| Q1 2023 | -3.3% | +1.5% | -7.4% | |
| Q4 2022 | -2.4% | -0.9% | -7.7% | |
| Q3 2022 | -6.3% | -5.3% | +6.0% | |
| Q2 2022 | +7.3% | +10.4% | +3.4% | |
| Q1 2022 | +4.2% | +5.1% | +2.1% | |
| Q4 2021 | -9.4% | -8.5% | -7.4% | |
| Q3 2021 | +6.5% | +11.8% | +19.3% | |
| Q2 2021 | +0.2% | -1.2% | +6.6% | |
| Q1 2021 | -3.2% | -2.6% | -3.9% | |
| Q4 2020 | -7.1% | -6.5% | -9.4% | |
| Q3 2020 | +0.5% | -0.2% | +4.2% | |
| Q2 2020 | -1.8% | -2.8% | -37.9% | |
| Q1 2020 | -2.6% | -4.4% | +12.8% | |
| Q4 2019 | -1.3% | +3.7% | -12.6% | |
| Q3 2019 | +2.5% | +6.5% | +14.8% | |
| Q2 2019 | -1.9% | -4.2% | -5.4% | |
| Q1 2019 | -0.5% | +0.0% | +4.1% | |
| Q4 2018 | -3.1% | +1.7% | -2.9% | |
| Q3 2018 | +4.9% | -0.8% | +1.0% | |
| Q2 2018 | -1.5% | +4.7% | -1.0% | |
| Q1 2018 | +1.7% | +2.9% | +14.0% | |
| Q4 2017 | -1.4% | -1.4% | -6.4% | |
| Q3 2017 | -1.9% | -3.2% | -2.5% | |
| Q2 2017 | +1.7% | +1.2% | +3.0% | |
| Q1 2017 | -1.8% | -5.0% | -5.5% | |
| Q4 2016 | -2.5% | +4.6% | -2.7% | |
| Q3 2016 | -0.8% | +1.2% | +8.9% | |
| Q2 2016 | -2.5% | -6.2% | -5.6% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +2.7% | — | — | |
| Q3 2014 | +9.0% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | -0.9% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q4 2012 | +1.7% | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q2 2012 | -5.2% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -7.2% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q4 2010 | +3.2% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | +0.3% | — | — | |
| Q3 2010 | +4.0% | — | — | |
| Q3 2009 | +4.0% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2010 | -0.6% | — | — | |
| Q1 2010 | -8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro